On the maternal side of the placenta, CPT2 only had a significant decrease in all pre-eclampsia (−25.6%), EOPE (−28.4%), SPE (−34.6%), and IUGR (−38.0%) groups when compared to the controls. This evidence concerns the gene CPT2 and fetal growth restriction.